Actively Recruiting

Phase 4
Age: 18Years - 90Years
All Genders
NCT07383103

Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock

Led by Northern Jiangsu People's Hospital · Updated on 2026-03-04

336

Participants Needed

1

Research Sites

147 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy and safety of the combination therapy of hydrocortisone and fludrocortisone among adult patients with septic shock.

CONDITIONS

Official Title

Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock

Who Can Participate

Age: 18Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged between 18 and 90 years
  • Diagnosis of septic shock within 12 hours prior to enrollment
Not Eligible

You will not qualify if you...

  • Use of systemic corticosteroid therapy within the last 3 months before septic shock
  • Receiving high-dose steroid therapy
  • Having immunosuppression
  • Being pregnant
  • Known allergy to hydrocortisone or fludrocortisone
  • Presence of gastrointestinal bleeding, perforation, or conditions requiring fasting
  • Expected death from a preexisting disease within 90 days after randomization
  • Refusal by attending staff or patient's family
  • Current participation in another clinical trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Northern Jiangsu People's Hospital

Yangzhou, Jiangsu, China, 225000

Actively Recruiting

Loading map...

Research Team

Q

Qingquan Lyu, Master

CONTACT

X

Xiaohua Gu, Master

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here